Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) EBT (2016 - 2025)

Immucell's EBT history spans 16 years, with the latest figure at -$2.8 million for Q4 2025.

  • For Q4 2025, EBT fell 646.65% year-over-year to -$2.8 million; the TTM value through Dec 2025 reached -$1.0 million, up 52.09%, while the annual FY2025 figure was -$1.0 million, 52.09% up from the prior year.
  • EBT reached -$2.8 million in Q4 2025 per ICCC's latest filing, down from -$135292.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $1.4 million in Q1 2025 to a low of -$2.8 million in Q4 2025.
  • Average EBT over 5 years is -$575013.0, with a median of -$546257.0 recorded in 2021.
  • Peak YoY movement for EBT: tumbled 2314.25% in 2022, then surged 431.91% in 2025.
  • A 5-year view of EBT shows it stood at $75256.0 in 2021, then crashed by 2314.25% to -$1.7 million in 2022, then soared by 31.68% to -$1.1 million in 2023, then soared by 145.73% to $520591.0 in 2024, then tumbled by 646.65% to -$2.8 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's EBT are -$2.8 million (Q4 2025), -$135292.0 (Q3 2025), and $503784.0 (Q2 2025).